Parkinson's disease (PD) is the second most common neurodegenerative disease globally.
Current drugs only alleviate symptoms without halting disease progression, making rodent …

Nuclear pore complexes (NPCs) are embedded in the nuclear envelope and facilitate the
exchange of macromolecules between the nucleus and cytoplasm in eukaryotic cells. The …

Parkinson's disease (PD) and osteoporosis are prevalent chronic conditions that impact a
significant proportion of the aging population. Observational and longitudinal studies …

The effect of the modulators of the mitochondrial ATP-dependent potassium channel
(mitoKATP) on the structural and biochemical alterations in the substantia nigra and brain …

Deep-brain subthalamic nucleus stimulation (DBS-STN) has become a well-established
therapeutic option for advanced Parkinson's disease (PD). While the motor benefits of DBS …

Neurotoxins have been extensively investigated, particularly in the field of neuroscience.
They induce toxic damage, oxidative stress, and inflammation on neurons, triggering …

Among the symptoms of Parkinson's disease (PD), apathy comprises a set of behavioral,
affective, and cognitive features that can be classified into several subtypes. However, the …

Background Parkinson's disease (PD) is a neurodegenerative disorder caused by dopamine
(DA) neuronal dysfunction. Although DA agonists and N-methyl-D-aspartate receptor …

Parkinson's disease (PD) is characterized by the degeneration of dopaminergic nigrostriatal
inputs, which causes striatal network dysfunction and leads to pronounced motor deficits …

Alterations to the dopaminergic system can have several consequences on behaviour such
as the development of disorders like addiction, schizophrenia, and Parkinsons. The lateral …